Clinical Trial

A Study of MT-0551 in Patients With Systemic Sclerosis

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The study will verify the superiority of MT-0551 to placebo at 26 weeks after treatment initiation in systemic sclerosis (SSc) patients using the modified Rodnan Total Skin thickness Score (mRTSS) as a measure of skin thickening. The safety and pharmacokinetics will also be investigated.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2022-01-06; most recent amendment 2025-12-04.
Status change: Recruiting → Active, Not Recruiting 2025-06-11
Status change: Not Yet Recruiting → Recruiting 2022-08-08
Trial Details
NCT Number NCT05198557
Lead Sponsor Tanabe Pharma Corporation
Conditions Systemic Sclerosis
Enrollment 80 participants
Start Date 2022-07-20
Primary Completion 2025-07-31 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2025-12-08